v3.26.1
Business Segment Information - Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Business Segment Reconciliation Information        
Net sales $ 185,610 $ 124,120 $ 336,181 $ 230,784
Cost of sales 34,016 26,896 67,355 51,212
Interest income 2,279 2,574 4,710 5,650
Interest expense 1,459 1,151 2,584 2,314
Income tax provision 656 248 1,140 574
Net loss (18,377) (19,657) (38,160) (37,803)
Development and Commercialization of Ophthalmic Therapies        
Business Segment Reconciliation Information        
Net sales 185,610 124,120 336,181 230,784
Cost of sales 34,016 26,896 67,355 51,212
Sales, marketing and distribution 56,609 40,025 102,898 74,468
Research and development 32,894 25,802 61,865 48,724
Clinical 18,407 10,736 33,581 20,167
General and administrative 59,451 43,350 106,105 79,580
Acquired in-process research and development 1,500 0 1,500 0
Significant segment expenses 202,877 146,809 373,304 274,151
Interest income 2,279 2,574 4,710 5,650
Interest expense (1,459) (1,151) (2,584) (2,314)
Other (expense) income, net (1,274) 1,857 (2,023) 2,802
Income tax provision 656 248 1,140 574
Net loss $ (18,377) $ (19,657) $ (38,160) $ (37,803)